Abraxane and Temodar Plus Genasense in Advanced Melanoma
This study is designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of combination treatment with Temodar®, Genasense®, and Abraxane® in chemotherapy-naïve subjects with advanced melanoma and normal lactate dehydrogenase (LDH).
Melanoma
DRUG: Genasense® (oblimersen)|DRUG: Abraxane® (paclitaxel protein-bound particles for injectable suspension)|DRUG: Temodar® (temozolomide)
Safety based on adverse event reports and clinical laboratory findings, During protocol therapy prior to the start of and during each cycle and up to 30 days after last dose of protocol therapy
Response rate (including rate of complete response), At the end of each cycle during protocol therapy, with follow-up every 2 months for up to 2 years from date of registration|Duration of response (including the rate of durable response), At the end of each cycle during protocol therapy, with follow-up every 2 months for up to 2 years from date of registration|Time to disease progression, At the end of each cycle during protocol therapy, with follow-up every 2 months for up to 2 years from date of registration|Incidence of brain metastasis, At the end of each cycle during protocol therapy, with follow-up every 2 months for up to 2 years from date of registration|Survival, 12,15, and 18 months from date of registration, with follow-up every 2 months for up to 2 years from date of registration|Correlations of drug concentrations, intracellular Bcl-2 content, and response, Cycle 1
This study is designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of combination treatment with Temodar®, Genasense®, and Abraxane® in chemotherapy-naïve subjects with advanced melanoma and normal lactate dehydrogenase (LDH).